Background
Methods
Study design and data collection
Inclusion criteria |
N
|
---|---|
Adults with ALL in CR1 or CR2 allografted from MSD or UD 10/10 or UD 9/10 from January 2000 to December 2017 | 10,418 |
Myeloablative conditioning | 8400 |
Available information | |
Immunophenotype B or T and Philadelphia status | 5540 |
MRD status before transplantation reported | 2780 |
Statistical methods
Results
Demographics and transplant details
Characteristic | MRD negative | MRD positive |
P
|
---|---|---|---|
N
| 1816 | 964 | |
Median follow-up, (months, IQR) | 39.70 (12.89–84.20) | 44.56 (16.07–82.07) | 0.410 |
Median age (years, range, IQR) | 36 (18–70, 26–46) | 38 (18–72, 28–48) | < 0.001 |
Median time dg to HCT (months, range, IQR) | 5.7 (1.9–130, 4.6–8) | 5.6 (2.3–123, 4.5–7.7) | 0.182 |
Median year of HCT (range) | 2012 (2000–2017) | 2012 (2000–2017) | 0.687 |
Median donor age (years, range, IQR, missing) | 34 (4–73, 26–44, 643) | 35 (10–72, 27–44, 293) | 0.080 |
In vivo TCD | 0.221 | ||
No in vivo TCD | 1099 (62%) | 565 (60%) | |
In vivo TCD | 670 (38%) | 381 (40%) | |
Data missing | 47 | 18 | |
Remission status at HCT | 0.518 | ||
CR1 | 1580 (87%) | 847 (88%) | |
CR2 | 236 (13%) | 117 (12%) | |
ALL subtype | < 0.001 | ||
B-ALL Ph-negative | 479 (26%) | 181 (19%) | |
B-ALL Ph-positive | 882 (49%) | 639 (66%) | |
T-ALL | 455 (25%) | 144 (15%) | |
Karnofsky score at HCT | 0.203 | ||
< 80% | 60 (4%) | 41 (5%) | |
> =80% | 1639 (96%) | 861 (95%) | |
Data missing | 117 | 62 | |
Engraftment | 0.459 | ||
Engrafted | 1732 (98%) | 925 (99%) | |
Graft failure | 29 (1.7%) | 12 (1.3%) | |
Data missing | 55 | 27 | |
Source of stem cells | 0.008 | ||
Bone marrow | 409 (23%) | 261 (27%) | |
Blood | 1407 (78%) | 703 (73%) | |
Donor type | 0.268 | ||
Matched sibling | 1041 (57%) | 531 (55%) | |
Unrelated 10/10 match | 575 (32%) | 308 (32%) | |
Unrelated 9/10 match | 200 (11%) | 125 (13%) | |
Conditioning | 0.628 | ||
Chemotherapy-based | 435 (24%) | 223 (23%) | |
TBI containing | 1381 (76%) | 741 (77%) | |
Patient sex | 0.285 | ||
Male | 1097 (60%) | 603 (63%) | |
Female | 717 (40%) | 361 (37%) | |
Data missing | 2 | 0 | |
Donor sex | 0.267 | ||
Male | 1107 (62%) | 606 (64%) | |
Female | 693 (39%) | 346 (36%) | |
Data missing | 16 | 12 | |
Donor–recipient sex mismatch | 0.411 | ||
Female to male | 391 (22%) | 195 (20%) | |
Other | 1409 (78%) | 762 (80%) | |
Data missing | 16 | 7 | |
Patient CMV serology | 0.950 | ||
Negative | 637 (37%) | 342 (37%) | |
Positive | 1090 (63%) | 582 (63%) | |
Data missing | 89 | 40 | |
Donor CMV serology | 0.690 | ||
Negative | 790 (46%) | 414 (45%) | |
Positive | 927 (54%) | 502 (55%) | |
Data missing | 99 | 48 | |
CMV donor/recipient | 0.975 | ||
Negative to negative | 450 (27%) | 239 (27%) | |
Positive to negative | 176 (10%) | 99 (11%) | |
Negative to positive | 317 (19%) | 166 (18%) | |
Positive to positive | 743 (44%) | 398 (44%) | |
Data missing | 130 | 62 | |
HCT-comorbidity index | 0.128 | ||
1 or 2 | 529 (85%) | 271 (81%) | |
> =3 | 92 (15%) | 62 (19%) | |
Data missing | 1195 | 631 | |
GVHD prevention | 0.054 | ||
Cyclosporin | 124 (7%) | 60 (6%) | |
Cyclosporin and MTX | 1247 (70%) | 702 (74%) | |
Cyclosporin and MMF ± MTX | 181 (10%) | 101 (11%) | |
Tacrolimus ± other | 115 (7%) | 41 (4%) | |
Other | 103 (6%) | 41 (4%) | |
Data missing | 46 | 19 | |
Acute GVHD | 0.139 | ||
Grade 0–I | 1156 (67%) | 594 (64%) | |
Grade II–IV | 564 (33%) | 329 (36%) | |
Data missing | 96 | 41 | |
Donor lymphocyte infusion | < 0.001 | ||
None received | 1681 (93%) | 846 (88%) | |
Pre-emptive | 36 (2%) | 48 (5%) | |
After relapse | 97 (5%) | 67 (7%) | |
Data missing | 2 | 3 |
Univariate analysis
Multivariate analysis
N = 2156 | RI | NRM | LFS | OS | GRFS | Acute GVHD II-IV | Acute GVHD III-IV | Chronic GVHD | Extensive cGVHD | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HR (95% CI) |
P
| HR (95% CI) |
P
| HR (95% CI) |
P
| HR (95% CI) |
P
| HR (95% CI) |
P
| HR (95% CI) |
P
| HR (95% CI) |
P
| HR (95% CI) |
P
| HR (95% CI) |
P
| |
MRD pos vs neg | 1.51 (1.26–1.80) | < 0.001 | 0.99 (0.80–1.23) | 0.928 | 1.26 (1.10–1.44) | 0.001 | 1.19 (1.02–1.39) | 0.028 | 1.25 (1.10–1.41) | < 0.001 | 1.12 (0.96–1.32) | 0.161 | 1.09 (0.80–1.48) | 0.585 | 1.00 (0.85–1.18) | 0.996 | 0.99 (0.79–1.24) | 0.949 |
Ph neg B-ALL | 1 | – | 1 | – | 1 | – | 1 | – | 1 | – | 1 | – | 1 | – | 1 | – | 1 | – |
Ph pos B-ALL | 0.94 (0.75–1.18) | 0.609 | 1.43 (1.07–1.91) | 0.015 | 1.12 (0.94–1.33) | 0.198 | 0.94 (0.72–1.14) | 0.531 | 1.02 (0.87–1.19) | 0.818 | 0.96 (0.79–1.17) | 0.663 | 0.87 (0.61–1.25) | 0.456 | 0.95 (0.78–1.16) | 0.637 | 1.08 (0.82–1.42) | 0.578 |
T-ALL | 1.11 (0.86–1.43) | 0.445 | 1.11 (0.78–1.58) | 0.554 | 1.13 (0.92–1.39) | 0.246 | 1.06 (0.85–1.33) | 0.611 | 1.03 (0.86–1.25) | 0.720 | 1.10 (0.87–1.39) | 0.429 | 0.84 (0.54–1.30) | 0.440 | 0.84 (0.66–1.06) | 0.138 | 1.01 (0.73–1.41) | 0.938 |
Age (per 10 years) | 1.03 (0.96–1.11) | 0.369 | 1.32 (1.22–1.42) | < 0.001 | 1.15 (1.09–1.21) | < 0.001 | 1.21 (1.14–1.28) | < 0.001 | 1.12 (1.06–1.18) | < 0.001 | 1.08 (1.01–1.15) | 0.019 | 1.09 (0.97–1.22) | 0.170 | 1.07 (1.01–1.14) | 0.025 | 1.06 (0.97–1.15) | 0.218 |
Year of HCT | 0.97 (0.95–0.99) | 0.042 | 0.97 (0.94–1.00) | 0.053 | 0.97 (0.95–0.99) | 0.005 | 0.98 (0.95–0.10) | 0.030 | 0.99 (0.97–1.00) | 0.096 | 0.98 (0.96–0.10) | 0.032 | 0.97 (0.93–1.01) | 0.173 | 0.97 (0.94–0.99) | 0.002 | 1.01 (0.98–1.04) | 0.628 |
CR2 vs CR1 | 2.29 (1.83–2.88) | < 0.001 | 1.63 (1.2–2.23) | 0.002 | 2.02 (1.68–2.42) | < 0.001 | 2.11 (1.72–2.59) | < 0.001 | 1.70 (1.43–2.03) | < 0.001 | 1.21 (0.97–1.52) | 0.096 | 1.58 (1.06–2.36) | 0.025 | 1.07 (0.82–1.40) | 0.604 | 1.19 (0.82–1.73) | 0.358 |
KPS > =90% | 1.09 (0.88–1.35) | 0.418 | 1.14 (0.89–1.47) | 0.297 | 1.12 (0.95–1.31) | 0.173 | 1.01 (0.85–1.21) | 0.896 | 1.03 (0.90–1.19) | 0.648 | 0.98 (0.82–1.18) | 0.839 | 0.97 (0.69–1.36) | 0.841 | 1.02 (0.85–1.22) | 0.826 | 1.08 (0.84–1.39) | 0.543 |
UD 10/10 | 0.66 (0.52–0.83) | < 0.001 | 1.91 (1.45–2.51) | < 0.001 | 1.02 (0.86–1.22) | 0.793 | 1.24 (1.01–1.51) | 0.038 | 1.14 (0.97–1.34) | 0.125 | 1.66 (1.35–2.05) | < 0.001 | 2.02 (1.38–2.95) | < 0.001 | 1.39 (1.14–1.70) | 0.001 | 1.26 (0.96–1.66) | 0.099 |
UD 9/10 | 0.57 (0.42–0.81) | 0.001 | 2.10 (1.49–2.98) | < 0.001 | 1.01 (0.80–1.27) | 0.942 | 1.31 (1.01–1.69) | 0.043 | 1.02 (0.82–1.26) | 0.876 | 1.73 (1.33–2.26) | < 0.001 | 1.75 (1.04–2.94) | 0.035 | 1.32 (1.01–1.73) | 0.042 | 1.07 (0.73–1.59) | 0.716 |
Blood vs BM | 0.90 (0.73–1.10) | 0.288 | 1.07 (0.83–1.38) | 0.607 | 0.95 (0.82–1.11) | 0.534 | 0.39 (0.77–1.12) | 0.432 | 1.17 (1.01–1.36) | 0.043 | 1.08 (0.88–1.33) | 0.450 | 1.14 (0.79–1.65) | 0.496 | 1.44 (1.18–1.76) | < 0.001 | 1.83 (1.37–2.45) | < 0.001 |
Female vs male | 0.80 (0.67–0.96) | 0.018 | 0.93 (0.75–1.16) | 0.531 | 0.86 (0.75–0.99) | 0.031 | 0.86 (0.74–1.01) | 0.062 | 0.88 (0.77–0.99) | 0.039 | 0.94 (0.80–1.11) | 0.466 | 0.73 (0.53–0.10) | 0.047 | 0.92 (0.79–1.08) | 0.294 | 0.91 (0.73–1.14) | 0.411 |
Donor fem vs male | 0.66 (0.55–0.80) | < 0.001 | 1.29 (1.05–1.60) | 0.018 | 0.89 (0.77–1.02) | 0.098 | 0.97 (0.83–1.13) | 0.671 | 0.96 (0.85–1.09) | 0.519 | 1.11 (0.94–1.30) | 0.209 | 1.00 (0.73–1.37) | 0.986 | 1.33 (1.13–1.55) | < 0.001 | 1.23 (0.99–1.53) | 0.0593 |
Pt CMV pos vs neg | 0.93 (0.76–1.13) | 0.447 | 1.23 (0.98–1.56) | 0.081 | 1.06 (0.91–1.23) | 0.462 | 1.24 (1.05–1.47) | 0.014 | 1.02 (0.89–1.17) | 0.784 | 0.96 (0.80–1.13) | 0.603 | 1.01 (0.73–1.41) | 0.943 | 0.10 (0.84–1.19) | 0.972 | 1.04 (0.81–1.32) | 0.780 |
Dr CMV pos vs neg | 1.12 (0.92–1.36) | 0.276 | 0.89 (0.71–1.11) | 0.300 | 0.99 (0.86–1.15) | 0.931 | 0.95 (0.81–1.12) | 0.548 | 1.07 (0.94–1.23) | 0.315 | 1.08 (0.91–1.28) | 0.364 | 1.11 (0.80–1.54) | 0.523 | 1.18 (1.00–1.40) | 0.0567 | 1.30 (1.02–1.65) | 0.036 |
TBI vs chemo | 0.60 (0.49–0.74) | < 0.001 | 0.87 (0.68–1.12) | 0.292 | 0.70 (0.60–0.82) | < 0.001 | 0.75 (0.62–0.90) | 0.002 | 0.88 (0.76–1.03) | 0.104 | 1.18 (0.95–1.46) | 0.126 | 1.02 (0.69–1.51) | 0.922 | 1.23 (0.99–1.52) | 0.0647 | 1.27 (0.93–1.75) | 0.131 |
In vivo TCD vs no TCD | 1.22 (0.97–1.53) | 0.090 | 0.68 (0.52–0.88) | 0.004 | 0.94 (0.79–1.12) | 0.494 | 0.84 (0.69–1.02) | 0.077 | 0.75 (0.64–0.88) | < 0.001 | 0.72 (0.59–0.89) | 0.002 | 0.51 (0.33–0.75) | < 0.001 | 0.58 (0.47–0.71) | < 0.001 | 0.48 (0.36–0.64) | < 0.001 |
Center (frailty) | – | 0.314 | – | 0.17 | – | 0.295 | – | 0.015 | – | 0.019 | – | < 0.001 | – | < 0.001 | – | 0.028 | – | 0.004 |